Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer

被引：40
|
作者：
Zhu, Menghai [1 ]
Liu, Changzhen [2 ]
Li, Shifei [1 ]
Zhang, Shudong [1 ]
Yao, Qi [1 ]
Song, Qingkun [3 ]
机构：
[1] Capital Med Univ, Peking Univ, Sch Clin Med 9, Beijing Shijitan Hosp,Dept Orthoped, Beijing, Peoples R China
[2] China Acad Chinese Med Sci, Beijing Key Lab Res Chinese Med Prevent & Treatme, Expt Res Ctr, Beijing, Peoples R China
[3] Beijing Shijitan Hosp, Dept Sci & Technol, Beijing, Peoples R China
来源：
SCIENTIFIC REPORTS | 2017年 / 7卷
关键词：
SKELETAL-RELATED EVENTS; MULTIPLE-MYELOMA; SIGNALING PATHWAY; TURNOVER MARKERS; MINERAL DENSITY; SERUM-LEVELS; CATENIN; EXPRESSION; CELLS; DICKKOPF-1;
D O I：
10.1038/s41598-017-11913-7
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Breast cancer is the second leading cause of cancer-related deaths among women worldwide. Many patients suffer from bone metastasis. Sclerostin, a key regulator of normal bone remodeling, is critically involved in osteolytic bone diseases. However, its role in breast cancer bone metastasis remains unknown. Here, we found that sclerostin was overexpressed in breast cancer tumor tissues and cell lines. Inhibition of sclerostin by antibody (Scl-Ab) significantly reduced migration and invasion of MDA-MB-231 and MCF-7 cells in a time-and dose-dependent manner. In xenograft model, sclerostin inhibition improved survival of nude mice and prevented osteolytic lesions resulting from tumor metastasis. Taken together, sclerostin promotes breast cancer cell migration, invasion and bone osteolysis. Inhibition of sclerostin may serve as an efficient strategy for interventions against breast cancer bone metastasis or osteolytic bone diseases.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer
    Menghai Zhu
    Changzhen Liu
    Shifei Li
    Shudong Zhang
    Qi Yao
    Qingkun Song
    [J]. Scientific Reports, 7
  • [2] The effect of platycodin D on tumor-induced osteolysis in breast cancer bone metastasis
    Lee, Sun Kyoung
    Park, Kwang Kyun
    Kim, Yeong-Shik
    Ha, Young-Wan
    Chung, Won Yoon
    [J]. CANCER TREATMENT REVIEWS, 2008, 34 : S64 - S64
  • [3] Plumbagin Inhibits Breast Tumor Bone Metastasis and Osteolysis by Modulating the Tumor-Bone Microenvironment
    Li, Z.
    Xiao, J.
    Wu, X.
    Li, W.
    Yang, Z.
    Xie, J.
    Xu, L.
    Cai, X.
    Lin, Z.
    Guo, W.
    Luo, J.
    Liu, M.
    [J]. CURRENT MOLECULAR MEDICINE, 2012, 12 (08) : 967 - 981
  • [4] Breast Cancer Metastasis to Bone: Mechanisms of Osteolysis and Implications for Therapy
    Wende Kozlow
    Theresa A. Guise
    [J]. Journal of Mammary Gland Biology and Neoplasia, 2005, 10 : 169 - 180
  • [5] Breast cancer metastasis to bone: Mechanisms of osteolysis and implications for therapy
    Kozlow, W
    Guise, TA
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2005, 10 (02) : 169 - 180
  • [6] The RANKL inhibitor osteoprotegerin (OPG) inhibits tumor growth, prevents tumor-induced osteolysis, and significantly improves survival in a mouse model of breast cancer bone metastasis
    Canon, J.
    Roudier, M.
    Bryant, R.
    Radinsky, R.
    Dougall, W.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 166 - 167
  • [7] Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis
    Cher, ML
    Biliran, HR
    Bhagat, S
    Meng, YH
    Che, MX
    Lockett, J
    Abrams, J
    Fridman, R
    Zachareas, M
    Sheng, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) : 7847 - 7852
  • [8] Prevention of tumor growth and tumor-induced osteolysis by the RANKL inhibitor osteoprotegerin (OPG) is associated with significant improvement in survival using a mouse model of breast cancer bone metastasis
    Canon, J.
    Roudier, M.
    Bryant, R.
    Radinsky, R.
    Dougall, W.
    [J]. BONE, 2007, 40 (06) : S145 - S145
  • [9] ZK-EPO, a third-generation epothilone inhibits tumor growth and osteolysis in a mouse model of breast cancer bone metastasis
    Kakonen, S.
    Hoffmann, J.
    Klar, U.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 35 - 35
  • [10] ZK 304709, the multi-target tumor growth Inhibitor™ (MTGI™), inhibits osteolysis and tumor burden in a breast cancer bone metastasis model.
    Käkönen, S.
    Bosslet, K.
    Siemeister, G.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S28 - S28
12345